Flashpoint Announces New Joint Venture Fund Targeting $150 Million to Invest in Direct Secondaries
Flashpoint announces its partnership with renowned growth investor, Roman Ivaniuk through the establishment of a joint venture fund to invest in direct secondary opportunities in growth stage companies in Europe.
Flashpoint is an international tech investment manager with over $400 million AUM focused on tech companies originating from Europe and Israel. Roman Ivaniuk is an investment banker with 12+ years of experience, 50+ closed deals (VC, PE, pre-IPO, IPO), and $1B+ total closed deals value. He is a Founder and former MP of GR Capital (a Pan-European venture fund), the current Founder and MP of an investment company BrightOne Capital.
The fund’s strategy will be to support prominent growth-stage tech companies in Europe through investments in direct secondary opportunities. The unique synergy of this partnership will be directed towards raising $150 million, with an initial $50 million for the first closing. The partners have been present in the EU/Israel VC ecosystem for 10+ years. They established direct relationships with founders and investors alike, giving them unique insights into market trends and access to exclusive deal flow.
Flashpoint made 13 primary investments into growth-stage companies within its portfolio of 47 active investments. This is the second Flashpoint fund investing in direct secondaries: the predecessor, Flashpoint Secondary Fund I (“FSF I”), was launched in 2020 and was anchored by the Scheinberg family office. The current portfolio of FSF I consists of 6 later-stage companies, including K2View, Printify, Preply, Mesh Payments, Booksy, and Landtech.
Roman Ivaniuk’s track record covers investments in WeFox, McMackler, Glovo, Deliveroo, Sennder, Azimo and Flashcenpost among others. There were 10 successful exits in his portfolio in 2016-2021. He also has a strong private equity experience in Ukraine, having developed the country’s largest healthcare chain Dobrotut.
Flashpoint, led by Alex Konoplyasty, Michael Szalontay, and Igor Bilous, is renowned for its strategic investments in innovative technology startups originating from Emerging Europe and Israel. Flashpoint manages five funds: 3 VC funds, 1 Growth Debt Fund, and 1 Direct Secondaries Fund. Investors in Flashpoint’s funds include more than 130 major family offices and HNWIs. The funds have made investments in over 66 companies including Guesty, Chili Piper, and Office RnD. Flashpoint has completed fifteen exits, including the sale of its stakes in Shazam (to Apple), Chess.com (to PokerStars founders and General Atlantic), Marketman (to PSG), and Gurushots (to Zedge), Comeet (to Boathouse Capital), etc.
Currently, Roman is focused on late-stage VC and Growth investments in the EU/UK, on globalization and expansion of profitable companies with Ukrainian roots, cross-border transactions, and international fundraising.
Michael Szalontay, General Partner at Flashpoint, said: “We are delighted to announce our partnership with Roman Ivaniuk on this innovative joint venture fund. Together, we can combine our substantial networks and track records across CEE and Israel to deliver significant value and expertise to investors and investees alike. We are excited about our prospects as we pursue our goal of raising $150 million which we will allocate to some of the world’s most exciting growth stories.”
Roman Ivaniuk, Managing Partner at Flashpoint RI Secondary Fund II, said: “This joint venture is an extension of our successful investments in the EU tech companies with their further expansion. Flashpoint VC has a strong CEE base and a great VC track record. I helped to globalize my portfolio of growth companies in the CEE region and know every step from the inside. Together we have a cool overlap and unique strategy. Our expertise and direct access to the companies is a great value for our Secondary Fund. I feel confidence and excitement toward our new joint venture and our future investment opportunities.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231031982284/en/
Contact information
Maria Eliseeva
Head of PR/Marketing at Flashpoint VC
Maria.e@flashpointvc.com
+371 26380366
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VIOOH Shares Industry-first Carbon Emissions Measurement Hitting 18% Below Benchmark11.12.2023 09:00:00 CET | Press release
Today, VIOOH, the leading premium global digital out of (DOOH) home supply-side platform, announced a partnership with the Carbon Intelligence Platform, Cedara, a supporter of Ad Net Zero. In an industry first for a programmatic DOOH (prDOOH) player, VIOOH has shared publicly its impression intensity carbon emissions (grams CO2e) per ad impression for 2022, which is 18% below the programmatic open web benchmark. Based on Cedara’s measurement, VIOOH generated 0.28 grams CO2e per ad impression in 2022, well below the Cedara ad platform benchmark of 0.34, which is based on programmatic open web vendor data. VIOOH worked closely with Cedara on a comprehensive greenhouse gas (GHG) inventory assessment across its operations, including programmatic media activity, which contributes the majority of Scope 3 emissions. As part of its measurement process, Cedara not only analysed data sets from business operations, but also activity data from media delivery, data centres, and media owners, amongs
Hexadrone Starts C5 and C6 Drone Type Examination After Successful GAP Analysis of The TUNDRA 2’ Specification by Notified Body11.12.2023 08:30:00 CET | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH. The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more. “Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European air
VINSSEN Co., Ltd. Successfully Supplies Hydrogen Fuel Cell for Industry Project in Singapore11.12.2023 08:00:00 CET | Press release
VINSSEN Co., Ltd. (CEO Chil-Han Lee), a company specializing in the production of electric and hydrogen hybrid propulsion systems, has successfully tested and delivered a hydrogen fuel cell system for a trial project involving several key industry partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210481971/en/ Hydrogen fuel cell power generation equipment is undergoing inspection before delivery (Photo: VINSSEN Co., Ltd.) VINSSEN is collaborating with Shell Singapore Pte. Ltd. (Shell) as the project sponsor, Seatrium Limited as the project developer, Penguin International Limited as the owner and operator of the vessel, and Air Liquide Singapore Private Limited as the hydrogen supplier. This project is a pilot to test the use of hydrogen fuel cells in maritime applications, marking the first step in confirming feasibility of hydrogen as a marine fuel. The hydrogen fuel cell system has been delivered from Korea and
New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation11.12.2023 08:00:00 CET | Press release
Masimo (NASDAQ: MASI) today announced the findings of a retrospective study published in the Journal of Anesthesia in which Dr. Yu Jeong Bang and colleagues at the Samsung Medical Center, Sungkyunkwan University School of Medicine, in Seoul, South Korea, investigated the association of Masimo ORi™ and the arterial partial pressure of oxygen (PaO2) in 554 patients who underwent non-cardiac thoracic surgery during one-lung ventilation (OLV), making this study the largest to date on ORi. The researchers found that ORi values “were significantly correlated with PaO2 measured simultaneously” and that ORi “could provide useful information on arterial oxygenation even during one-lung ventilation.”1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210873994/en/ Masimo Root® with ORi™ (Photo: Business Wire) Noninvasive, continuous Masimo ORi provides continuous, real-time insight into the oxygenation of hemoglobin in the moderate hy
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement11.12.2023 07:00:00 CET | Press release
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are today announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231210383233/en/ The deal provides Ferring with exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration. The financial details of this deal are undisclosed. “This agreement is the latest in Ferring’s long term mission to maximise the therapeutic potential of the gut microbiome for the benefit of patients. PharmaBiome’s unique technology enables identification and manufacturing of defined consortium live microbiome biotherapeutics that could reverse microbiome dysbiosis linked to disease,” said Carl Bilbo, Senior Vice President, Micr